Infliximab Partially Alleviates the Bite Force Reduction in a Mouse Model of Temporomandibular Joint Pain

Sang-Hyon KIM; Chang-Nam SON; Hyo-Jung LEE; Ho-Chan CHO; Sung-Won JUNG; Ji-An HUR; Won-Ki BAEK; Hye-Ra JUNG; Ji-Hee HONG.
Journal of Korean Medical Science ; : 552-558, 2015.
Artículo en Inglés | WPRIM | ID: wpr-99853

Documentos relacionados

  1. Infliximab partially alleviates the bite force reduction in a mouse model of temporomandibular joint pain.
  2. The effect of acute unilateral inflammation of the equine temporomandibular joint on the kinematics of mastication.
  3. Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment.
  4. In vivo antiarthritic activity of the ethanol extracts of stem bark and seeds of Calophyllum inophyllum in Freund's complete adjuvant induced arthritis.
  5. Lactic acidemia due to an infliximab infusion reaction.
  6. Comparative analysis of low-field magnetic resonance imaging in patients with rheumatoid arthritis treated with certolizumab pegol or infliximab.
  7. Increased ten-eleven translocation methylcytosine dioxygenase one in dorsal root ganglion contributes to inflammatory pain in CFA rats.
  8. Eosinophilic fasciitis in a pregnant woman with corticosteroid dependence and good response to infliximab.
  9. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry.
  10. Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.